Angela Epp

673 total citations
18 papers, 501 citations indexed

About

Angela Epp is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Angela Epp has authored 18 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Immunology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Angela Epp's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Immunotherapy and Immune Responses (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Angela Epp is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Immunotherapy and Immune Responses (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Angela Epp collaborates with scholars based in United States, United Kingdom and Italy. Angela Epp's co-authors include Carol J. Raport, Patrick W. Gray, Vicki L. Schweickart, Christi L. Wood, David Chantry, Shyra J. Gardai, Che‐Leung Law, Paola Romagnani, Sergio Romagnani and Neil C. Josephson and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Angela Epp

17 papers receiving 490 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angela Epp United States 10 299 204 104 81 62 18 501
Alexandra Joseph United States 7 166 0.6× 162 0.8× 98 0.9× 51 0.6× 85 1.4× 8 378
Vadim Deyev United States 13 238 0.8× 458 2.2× 92 0.9× 152 1.9× 56 0.9× 17 759
Steven Stein United States 8 128 0.4× 191 0.9× 49 0.5× 56 0.7× 70 1.1× 11 395
Riccardo Turrini Italy 12 282 0.9× 205 1.0× 91 0.9× 81 1.0× 23 0.4× 18 445
Joyce Setsuda United States 10 297 1.0× 290 1.4× 81 0.8× 177 2.2× 67 1.1× 11 658
Thamara Beyer Germany 8 205 0.7× 615 3.0× 57 0.5× 102 1.3× 33 0.5× 16 768
Mikio Ohtsuka Japan 15 394 1.3× 242 1.2× 162 1.6× 142 1.8× 41 0.7× 41 773
Salomé Glauzy France 14 98 0.3× 354 1.7× 48 0.5× 83 1.0× 34 0.5× 16 522
Heike Schmidlin Netherlands 8 133 0.4× 434 2.1× 46 0.4× 98 1.2× 23 0.4× 10 588
Ursula R. Sorg Germany 13 177 0.6× 186 0.9× 63 0.6× 254 3.1× 17 0.3× 26 580

Countries citing papers authored by Angela Epp

Since Specialization
Citations

This map shows the geographic impact of Angela Epp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Epp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Epp more than expected).

Fields of papers citing papers by Angela Epp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Epp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Epp. The network helps show where Angela Epp may publish in the future.

Co-authorship network of co-authors of Angela Epp

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Epp. A scholar is included among the top collaborators of Angela Epp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Epp. Angela Epp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Reis, Bernardo Sgarbi, Daniel J. Lee, Stefan N. Symeonides, et al.. (2024). 161P Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment. Annals of Oncology. 35. S279–S280. 2 indexed citations
2.
Epp, Angela, Weiping Zeng, Thomas S. Griffith, et al.. (2023). Abstract 1542: Generation of an antibody-drug conjugate-optimized TLR 7/8 agonist payload. Cancer Research. 83(7_Supplement). 1542–1542.
3.
Anderson, Sarah, Robert Lawrence, Aroon T. Chande, et al.. (2022). Abstract 1766: SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models. Cancer Research. 82(12_Supplement). 1766–1766. 2 indexed citations
4.
Gray, Elizabeth, Angela Epp, Michelle Ulrich, et al.. (2021). 854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models. SHILAP Revista de lepidopterología. A895–A895. 3 indexed citations
5.
Schwartz, Alyssa D., Robert Lawrence, Sarah E. Anderson, et al.. (2021). Abstract 50: Targeting Sialyl-Thomsen nouveau (STn) antigen with the SGN-STNV antibody-drug conjugate is effective in preclinical studies. Cancer Research. 81(13_Supplement). 50–50. 11 indexed citations
6.
Gardai, Shyra J., Haley D. Neff‐LaFord, Angela Epp, et al.. (2016). Abstract 4994: SEA-CD40: from bench to bedside. Cancer Research. 76(14_Supplement). 4994–4994. 1 indexed citations
7.
Gardai, Shyra J., Angela Epp, Lori Westendorf, et al.. (2015). Abstract 2472: SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities. Cancer Research. 75(15_Supplement). 2472–2472. 5 indexed citations
8.
Gardai, Shyra J., Angela Epp, & Che‐Leung Law. (2015). Abstract 2469: Brentuximab vedotin-mediated immunogenic cell death. Cancer Research. 75(15_Supplement). 2469–2469. 36 indexed citations
9.
Gardai, Shyra J., Angela Epp, May Kung Sutherland, et al.. (2015). A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors.. Journal of Clinical Oncology. 33(15_suppl). 3074–3074. 8 indexed citations
10.
Epp, Angela, Junli Feng, Yvette Latchman, et al.. (2011). Suppression of the Immune Response to FVIII in Hemophilia A Mice by Transgene Modified Tolerogenic Dendritic Cells. Molecular Therapy. 19(10). 1896–1904. 16 indexed citations
11.
Austin, Ryan J., et al.. (2011). Proteomic analysis of the androgen receptor via MS‐compatible purification of biotinylated protein on streptavidin resin. PROTEOMICS. 12(1). 43–53. 5 indexed citations
12.
Epp, Angela, et al.. (2009). Suppression of FVIII Inhibitor Formation in Hemophilic Mice by Delivery of Transgene Modified Apoptotic Fibroblasts. Molecular Therapy. 18(1). 214–222. 14 indexed citations
14.
Schweickart, Vicki L., Angela Epp, Carol J. Raport, & Patrick W. Gray. (2000). CCR11 Is a Functional Receptor for the Monocyte Chemoattractant Protein Family of Chemokines. Journal of Biological Chemistry. 275(13). 9550–9556. 64 indexed citations
15.
Stine, Johnny T., Christi L. Wood, Mark S. Hill, et al.. (2000). KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood. 95(4). 1151–1157. 167 indexed citations
16.
Chantry, David, Paola Romagnani, Carol J. Raport, et al.. (1999). Macrophage-Derived Chemokine Is Localized to Thymic Medullary Epithelial Cells and Is a Chemoattractant for CD3+, CD4+, CD8low Thymocytes. Blood. 94(6). 1890–1898. 89 indexed citations
17.
Chantry, David, Paola Romagnani, Carol J. Raport, et al.. (1999). Macrophage-Derived Chemokine Is Localized to Thymic Medullary Epithelial Cells and Is a Chemoattractant for CD3+, CD4+, CD8low Thymocytes. Blood. 94(6). 1890–1898. 9 indexed citations
18.
Chantry, David, Anthony J. DeMaggio, Carol J. Raport, et al.. (1998). Profile of human macrophage transcripts: insights into macrophage biology and identification of novel chemokines. Journal of Leukocyte Biology. 64(1). 49–54. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026